In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn's disease

Atreya, Raja; Neumann, Helmut; Neufert, Clemens; Waldner, Maximilian J.; Billmeier, Ulrike; Zopf, Yurdagül; Willma, Marcus; App, Christine; Münster, Tino; Keßler, Hermann; Maas, Stefanie; Gebhardt, B; Heimke-Brinck, Ralph; Reuter, Eva; Dörje, Frank; Rau, Tilman T.; Uter, Wolfgang; Wang, Thomas D.; Kießlich, Ralf; Vieth, Michael; Hannappel, Ewald; Neurath, Markus F.

doi:10.1038/nm.3462

Cited by 337 publications

(224 citation statements)

References 40 publications

Supporting

Mentioning

212

Contrasting

Unclassified

Order By: Relevance

“…Stenting an obstructing tumor with a radiation-emitting device is entering routine practice [32]. In vivo immunohistochemistry with fluorescent-tagged antibodies promises to revolutionize the endoscopic detection of mucosal pathology [33]. The future of endoscopy, as bright as modern light sources, will continue to bring new therapies from which our patients will benefit.…”

Section: Resultsmentioning

confidence: 99%

Fiberoptic Endoscopy: The Singular Transformative Event of Our Time

Wilcox

2014

Dig Dis Sci

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Fiberoptic Endoscopy: The Singular Transformative Event of Our Time

Wilcox

2014

Dig Dis Sci

View full text Add to dashboard Cite

“…Patients with high numbers of mTNF cells showed significantly higher short-term response rates (92%) at week 12 upon subsequent antiTNF therapy as compared to patients with low amounts of mTNF cells (15%). These data indicate that molecular imaging with fluorescent antibodies has the potential to predict therapeutic responses to biological treatment and can be used for personalized medicine in CD and other autoimmune or inflammatory disorders [76] . Due to their mode of action TNFαblockers may cause expected and paradoxical side effects, like "de novo psoriasis", described by Joyau et al [77] .…”

Section: CDmentioning

confidence: 88%

Pharmacological- and non-pharmacological therapeutic approaches in inflammatory bowel disease in adults

Leitner

Vogelsang

2016

WJGPT

View full text Add to dashboard Cite

Inflammatory bowel diseases (IBDs) are a group of chronic inflammatory conditions mainly of the colon and small intestine. Crohn's disease (CD) and ulcerative colitis (UC) are the most frequent types of IBD. IBD is a complex disease which arises as a result of the interaction of environmental, genetic and immunological factors. It is increasingly thought that alterations of immunological reactions of the patients to their own enterable bacteria (microfilm) may contribute to inflammation. It is characterized by mucosal and sub mucosal inflammation, perpetuated by infiltration of activated leukocytes. CD may affect the whole gastrointestinal tract while UC only attacks the large intestine. The therapeutic goal is to achieve a steroidfree long lasting remission in both entities. UC has the possibility to be cured by a total colectomy, while CD never can be cured by any operation. A lifelong intake of drugs is mostly necessary and essential. Medical treatment of IBD has to be individualized to each patient and usually starts with anti-inflammatory drugs. The choice what kind of drugs and what route administered (oral, rectal, intravenous) depends on factors including the type, the localization, and severity of the patient's disease. IBD may require immune-suppression to control symptoms such as prednisolone, thiopurines, calcineurin or sometimes folic acid inhibitors or biologics like TNF-α inhibitors or anti-integrin antibodies. For both types of disease (CD, UC) the same drugs are available but they differ in their preference in efficacy between CD and UC as 5-aminosalicylic acid for UC or budesonide for ileocecal CD. As therapeutic alternative the main mediators of the disease, namely the activated pro-inflammatory cytokine producing leukocytes can be selectively removed via two apheresis systems (Adacolumn and Cellsorba) in steroid-refractory or dependent cases. Extracorporeal photopheresis results in an increase of regulatory B cells, regulatory CD8 + T cells and T-regs Type 1. Both types of apheresis were able to induce clinical remission and mucosal healing accompanied by tapering of steroids.

show abstract

“…A high inflammatory burden also contributes to low serum drug levels [29,30]. Drug clearance is influenced by high tissue TNFa concentrations, low serum albumin concentration, and infliximab loss into the stool [31][32][33][34]. In response to these findings, proactive drug monitoring became a subject of intense investigation; for example, accelerated infliximab dosing for acute, severe ulcerative colitis can reduce short-term colectomy rates [35].…”

Section: Development Of Infliximabmentioning

confidence: 99%

The Impact of Therapeutic Antibodies on the Management of Digestive Diseases: History, Current Practice, and Future Directions

Sofia

Rubin

2017

Dig Dis Sci

View full text Add to dashboard Cite

The development of therapeutic antibodies represents a revolutionary change in medical therapy for digestive diseases. Beginning with the initial studies that confirmed the pathogenicity of cytokines in inflammatory bowel disease, the development and application of therapeutic antibodies brought challenges and insights into their potential and optimal use. Infliximab was the first biological drug approved for use in Crohn's disease and ulcerative colitis. The lessons learned from infliximab include the importance of immunogenicity and the influence of pharmacokinetics on disease response and outcomes. Building on this foundation, other therapeutic antibodies achieved approval for inflammatory bowel disease and many more are in development for several digestive diseases. In this review, we reflect on the history of therapeutic antibodies and discuss current practice and future directions for the field.

show abstract

In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn's disease

Cited by 337 publications

References 40 publications

Fiberoptic Endoscopy: The Singular Transformative Event of Our Time

Fiberoptic Endoscopy: The Singular Transformative Event of Our Time

Pharmacological- and non-pharmacological therapeutic approaches in inflammatory bowel disease in adults

The Impact of Therapeutic Antibodies on the Management of Digestive Diseases: History, Current Practice, and Future Directions

Contact Info

Product

Resources

About